[Wolfdev-Momentum] Are You A Penny Stock Fan?
Daily Stock Barometer
jxrtigujtgbx@erols.com
Tue, 21 Sep 2004 12:22:09 +0400
----85851299564235613
Content-Type: text/plain;
Content-Transfer-Encoding: quoted-printable
Breaking News At The Close Monday September 20, 2004
Genex Pharmaceuticals - 0TCBB Stock Symbol: GENX
The Good News Just Keeps on Coming for GENX.
Genex Pharmaceutical Signs New Product Distribution Agreements
Targeting China's Three Weal.thiest Provinces With a Population of
100 million, Company Sees Record Third Quarter 2004 Earnings
Monday September 20, 3:59 pm ET
TIANJIN, China BUSINESS WIRE Sept. 20, 2004 Genex Pharmaceutical,
Inc.; stock symbol: GENX; a Delaware corporation, is a pr0fitable
biomedical technology company with a revolutionary product for
treating various bone-related injuries called Reconstituted Bone
Xenograft, RBX, which is a medical device approved by the SFDA,
Chinese State Food and Drug Administration. RBX is suitable for
compound or complex bone fractures, compression fractures and
intractable fractures, bone defects, vertebral column or joint
rehabilitation and for bone absence after tumor removal such as a
bone cyst.
The Company announced that it has signed new product distribution
agreements with three national pharmaceutical distribution companies
located in the heavily populated JiangSu, ZheJiang and Shanghai
areas. These distributors have a broad distribution network in these
respective areas. These three areas are among the most populated and
most economically developed in China. These three areas collectively
have a population exceeding 120 milli0n. The greater metropolitan
Shanghai area alone has a population of approximately 25 milli0n.
Mr. Fuzhi Song, Chairman and CEO of Genex, stated, "The addition of
these three national pharmaceutical distributors covering some of
China's weal.thiest areas is significant to our national
distribution network. Our new distribution agreements cover almost
85% of such a large population base. As we continue to expand our
national distribution network, we expect strong third quarter
financial performance ending September 30."
Genex Pharmaceutical's RBX is well suited to treat numerous
bone-related injuries. Industry statistics estimate that over 15
milli0n people in China suffer from some sort of bone defect, and
the Company's RBX product is targeted to this potentially huge
market. Other applications of RBX include treatment of dental decay,
from which approximately 40 milli0n people every year in China
require treatment. Press Release Source: Genex Pharmaceutical, Inc.
About Genex Pharmaceutical, Inc.
Genex Pharmaceutical, Inc. is a biomedical technology company with
distinctive proprietary technology for an orthopedic device that
treats bone-related injuries. Headquartered in Tianjin, China, the
Company manufactures and distributes Reconstituted Bone Xenograft,
RBX, to 400 hospitals in 22 provinces throughout mainland China. RBX
is approved by the State Food and Drug Administration, SFDA, in
China, the Chinese government agency that regulates drugs and
medical devices. RBX offers a modern alternative to traditional
methods of treating orthopedic injuries.
Read the announcements GENX has made. Look at the Company. Read the
Filings. Do you see the Potential for Explosive Growth? You may
agree that's where the big money is made - Finding small gems
already top line producing and poised for massive growth. Consider
GENX for your portfolio today.
Good Luck and Successful Investing.
Safe Harb0r Statement Statements about the Company's future
expectations, including future revenue and earnings and all other
statements in this press release, other than historical facts, are
f0rward-looking statements and are made pursuant to safe harbor
provisions of the Securities Exchange Act of 1934. Such
f0rward-looking statements involve risks and uncertainties and are
subject to change at any time. The Company's actual results could
differ materially from expected results. In reflecting subsequent
events or circumstances, the Company undertakes no 0bligation to
update f0rward-looking statements.
DIS-CLAIMER: Information within this ema-il contains F0RWARD looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not
statements of historical fact and may be forward looking statements.
Forward looking statements are based on expectations, estimates and
projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results
or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through
the use of words such as projects , foresee, expects, will,
anticipates, estimates, believes, understands or that by statements
indicating certain actions may, could, or might occur. As with many
micro-cap stocks, today's company has additional risk factors worth
noting. Those factors include: a limited operating history: the
company advancing cash to related parties and a shareholder on an
unsecured basis: one vendor, a related party through a majority
stockholder, supplies ninety-seven percent of the company's raw
materials: reliance on two customers for over fifty percent of their
business and numerous related party transactions and the need to
raise capital.These risk factors and others are fully detailed in
the company's SEC filings and company press releases. We urge you to
read them before you invest. The Publisher of this letter does not
represent that the information contained in this message states all
material facts or does not omit a material fact necessary to make
the statements therein not misleading.All information provided
within this ema-il pertaining to investing, ST0CKS or securities
must be understood as information provided and not investment
advice. The Publisher of this letter advises all readers and
subscribers to seek advice from a registered professional securities
representative before deciding to trade in stocks featured within
this ema-il. None of the material within this report shall be
construed as any kind of investment advice or solicitation. Many of
these companies are on the verge of bankruptcy. You can lose all
your money by investing in this stock. The Publisher of this letter
is not a registered investment ADVIS0R. Subscribers should not view
information herein as legal, tax, accounting or investment advice.
Any reference to past performance s of companies are specially
selected to be referenced based on the favorable performance of
these companies. You would need perfect timing to acheive the
results in the examples given. There can be no assurance of that
happening.Remember, as always, past performance is ne-ver indicative
of future results and a thorough due diligence effort, including a
review of a company's filings, should be completed prior to
investing. In compliance with the Securities Act of 1933,
Section17 b, The Publisher of this letter discloses the receipt of
fourty two thousand dollars from a third party, not an officer,
director or affiliate shareholder for the circulation of this
report. Be aware of an inherent conflict of interest resulting from
such compensation due to the fact that this is a paid adver-tisement
and is not without bias. All factual information in this report was
gathered from public sources, including but not limited to Company
Websites, SEC Filings and Company Press Releases. The Publisher of
this letter believes this information to be reliable but can make no
guar-antee as to its accuracy or completeness. Use of the material
within this ema-il constitutes your acceptance of these terms.
----85851299564235613--